PMID- 23769811 OWN - NLM STAT- MEDLINE DCOM- 20131112 LR - 20230621 IS - 1095-6859 (Electronic) IS - 0090-8258 (Print) IS - 0090-8258 (Linking) VI - 130 IP - 3 DP - 2013 Sep TI - Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results. PG - 595-600 LID - S0090-8258(13)00838-X [pii] LID - 10.1016/j.ygyno.2013.06.005 [doi] AB - OBJECTIVE: Chromosomal gains at 3q26, 5p15 and 20q13 have been described in cervical precancer and cancer. We evaluated a novel fluorescence in situ hybridization (FISH) assay that detects gains at these three loci simultaneously as a possible biomarker for detecting cervical precancer. METHODS: Chromosomal copy numbers at 3q26, 5p15, 20q13 and the centromere of chromosome7 (cen7) in liquid-based cytology specimens from 168 women enrolled in the Biopsy Study were determined by FISH. The number of cells with >/= 3 or >/= 4 signals for a genomic locus was enumerated and diagnostic test performance measures were calculated using receiver operating characteristic (ROC) analyses. Sensitivity and specificity values were determined for the detection of CIN2+ and/or HSIL. RESULTS: The median number of cells with >/= 3 signals increased with the severity of cervical lesion for each genomic locus (p-trend<0.02 for each locus). ROC analysis for the number of cells with >/= 3 signals resulted in area under the curve values of 0.70 (95% CI: 0.54-0.86), 0.67 (0.52-0.83), 0.67 (0.51-0.83) and 0.78 (0.64-0.92) for 3q26, 5p15, 20q13 and cen7, respectively, for the detection of CIN2+ and/or HSIL. Positivity for gains at multiple loci resulted in only slightly better test performance measures than those for the individual probes for four distinct combinations of probes. CONCLUSIONS: Chromosomal gains at 3q26, 5p15, 20q13 and cen7 are associated with severity of cervical lesions. Further studies are required to quantify risk stratification of FISH assays for cervical cancer screening. CI - Published by Elsevier Inc. FAU - Luhn, Patricia AU - Luhn P AD - Division of Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. luhnpa@mail.nih.gov FAU - Houldsworth, Jane AU - Houldsworth J FAU - Cahill, Lynnette AU - Cahill L FAU - Schiffman, Mark AU - Schiffman M FAU - Castle, Philip E AU - Castle PE FAU - Zuna, Rosemary E AU - Zuna RE FAU - Dunn, S Terence AU - Dunn ST FAU - Gold, Michael A AU - Gold MA FAU - Walker, Joan AU - Walker J FAU - Wentzensen, Nicolas AU - Wentzensen N LA - eng GR - R44 CA139667/CA/NCI NIH HHS/United States GR - ZIA CP010124/ImNIH/Intramural NIH HHS/United States GR - ZIA CP010124-17/ImNIH/Intramural NIH HHS/United States GR - R44CA139667/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20130613 PL - United States TA - Gynecol Oncol JT - Gynecologic oncology JID - 0365304 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Area Under Curve MH - Biomarkers, Tumor/*genetics MH - Chromosomes, Human, Pair 20 MH - Chromosomes, Human, Pair 3 MH - Chromosomes, Human, Pair 5 MH - Chromosomes, Human, Pair 7 MH - Female MH - Humans MH - In Situ Hybridization, Fluorescence MH - *Polyploidy MH - Precancerous Conditions/*genetics MH - ROC Curve MH - Uterine Cervical Neoplasms/*genetics/pathology MH - Young Adult MH - Uterine Cervical Dysplasia/*genetics PMC - PMC3833871 MID - NIHMS502979 OTO - NOTNLM OT - 3q26 OT - Cervical cancer OT - FISH OT - Genomic gains OT - HPV EDAT- 2013/06/19 06:00 MHDA- 2013/11/13 06:00 PMCR- 2014/09/01 CRDT- 2013/06/18 06:00 PHST- 2013/02/22 00:00 [received] PHST- 2013/06/03 00:00 [revised] PHST- 2013/06/06 00:00 [accepted] PHST- 2013/06/18 06:00 [entrez] PHST- 2013/06/19 06:00 [pubmed] PHST- 2013/11/13 06:00 [medline] PHST- 2014/09/01 00:00 [pmc-release] AID - S0090-8258(13)00838-X [pii] AID - 10.1016/j.ygyno.2013.06.005 [doi] PST - ppublish SO - Gynecol Oncol. 2013 Sep;130(3):595-600. doi: 10.1016/j.ygyno.2013.06.005. Epub 2013 Jun 13.